Quantcast

Latest Cancer stem cell Stories

2014-07-07 10:11:17

McGill University Scientists at the Montreal Neurological Institute and Hospital, McGill University and McGill University Health Centre have shown that a member of the protein family known as SUMO (small ubiquitin-like modifier) is a key to why tumour cells multiply uncontrollably, especially in the case of glioblastoma. The SUMO family proteins modify other proteins and the SUMOylation of proteins are critical for many cellular processes. Identifying SUMO’s role in the cancer cell...

2014-07-01 11:10:06

American Association for Cancer Research A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy called adoptive T-cell therapy. This new approach may help develop more effective cancer immunotherapies, according to a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research. "This study...

2014-06-24 11:18:40

Penn State A virus not known to cause disease kills triple-negative breast cancer cells and killed tumors grown from these cells in mice, according to Penn State College of Medicine researchers. Understanding how the virus kills cancer may lead to new treatments for breast cancer. Adeno-associated virus type 2 (AAV2) infects humans but is not known to cause sickness. In prior studies, the researchers tested the virus on a variety of breast cancers that represent degrees of...

2014-06-17 08:28:31

Companies expect to commence first-in-human studies of Trx-1 in ovarian cancer in 1H15 BOSTON, June 17, 2014 /PRNewswire/ -- Australian oncology drug development company Novogen Limited [ASX:NRT; NASDAQ:NVGN] and CanTx Inc., its joint venture with Yale University, today announced the success of proof-of-concept pre-clinical studies confirming the potency of experimental drug, Trx-1, in the treatment of primary ovarian cancer when delivered into the peritoneal cavity. Based on the...

2014-06-16 12:29:10

CAMBRIDGE, Mass., June 16, 2014 /PRNewswire/ -- Boston Biomedical, a company focused on the research and development of novel cancer therapeutics targeting cancer stem cells (CSC), today provided a summary of the clinical data presented at the 2014 American Society of Clinical Oncology (ASCO) 50(th) annual meeting, held from May 30 to June 3, 2014, in Chicago, IL. Clinical data were presented for BBI608 and BBI503, novel agents targeting cancer stem cells that have been developed by...

2014-06-15 14:59:20

Broad Institute of MIT and Harvard Cellular makeup of glioblastoma more diverse than previously thought Scientists from the Broad Institute and Massachusetts General Hospital (MGH) have conducted a first-of-its-kind study that characterizes the cellular diversity within glioblastoma tumors from patients. The study, which looked at the expression of thousands of genes in individual cells from patient tumors, revealed that the cellular makeup of each tumor is more heterogeneous than...

2014-06-06 23:05:52

Patients with a particularly stubborn type of breast cancer could potentially benefit by supplementing radiation treatments with a generic, low-cost medication commonly prescribed to treat high cholesterol, according to a new study released today in Stem Cells Translational Medicine. Durham, NC (PRWEB) June 06, 2014 Patients with a particularly stubborn type of breast cancer could potentially benefit by supplementing radiation treatments with a generic, low-cost medication commonly...

2014-06-03 11:48:40

University of Colorado Denver At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials...

2014-06-02 23:09:54

Stem Cell Research Products Market says full-year 2013 analysis determines the size of the stem cell research products market to be $3.22 billion, and the stem cell therapies market to be $3.31 billion, for a total of $6.53 billion. Dallas, Texas (PRWEB) June 02, 2014 According to report “Stem Cell Research Products Market - Opportunities, Tools, and Technologies” as of 2014, several broad categories of stem cells exist, including:     Embryonic stem cells,...

2014-05-27 08:27:52

SYDNEY, May 27, 2014 /PRNewswire/ -- Novogen Limited (NASDAQ: NVGN, ASX:NRT), an oncology drug development company, today announced that it has achieved a key milestone with its super-benzopyran (SBP) drug program, having identified a number of SBP compounds with potent anti-cancer activity against human prostate cancer cells in vitro. As a result, Novogen has extended its preclinical SBP program to include prostate cancer as well as ovarian and brain cancers....


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.